Mounjaro 2026 price by access path
Mounjaro (tirzepatide) is Eli Lilly’s FDA-approved branded indication for Type 2 diabetes. The 2026 list price is $1,080 per 4-pen monthly supply (doses 2.5mg through 15mg). Your actual cost depends entirely on coverage and diagnosis:
- Commercial insurance with T2D diagnosis + savings card: $25/month. If your plan covers Mounjaro under a Type 2 diabetes ICD-10 code (E11.xx), the Lilly Mounjaro savings card drops covered copays to $25 with a $150 per-fill benefit and roughly $1,800 annual cap.
- Medicare Part D (T2D only): $40–$100/month. Standard Tier 3–4 specialty copay depending on plan.
- Cash pay at pharmacy: $1,050–$1,150/month. GoodRx rarely helps with Mounjaro — the drug is not generic and wholesale cost is too close to list.
- Mounjaro savings card without coverage: ~$930/month.A $150 off-list discount. Uncompetitive with Zepbound’s $499 LillyDirect vial for anyone whose primary goal is weight loss rather than T2D management.
- Compounded tirzepatide: $299–$449/month where still legally dispensed. Now restricted to documented individual medical necessity post-FDA delisting.
Mounjaro vs Zepbound — same molecule, very different economics
Mounjaro and Zepbound are both tirzepatide, same pens, same dose strengths. The difference is purely the FDA-approved indication — and that indication drives everything about cost and coverage:
- Mounjaro requires a Type 2 diabetes diagnosis for most commercial coverage. Your provider bills an E11.xx ICD-10 code; the prior auth is routine.
- Zepbound requires a BMI 30+ or BMI 27+ with one weight-related comorbidity (OSA, HTN, T2D, dyslipidemia). Prior auth is more variable.
- LillyDirect vials ($349–$499/month) are only offered for Zepbound, not Mounjaro. For cash-pay patients, Zepbound wins by a wide margin.
- Medicare covers Mounjaro for T2D but does not cover Mounjaro for obesity; Medicare covers Zepbound only for OSA.
If you have T2D, Mounjaro through your plan at $25/month is often the cheapest tirzepatide path. If you don’t have T2D, Zepbound — and specifically LillyDirect Zepbound vials — is almost always cheaper and easier to get covered. See the full tirzepatide vs semaglutide breakdown for efficacy data and the Wegovy vs Zepbound comparison for cost-per-pound math.
What commercial coverage actually looks like for T2D
Commercial insurance coverage of Mounjaro for Type 2 diabetes in 2026 is relatively strong — roughly 75–85% of large-employer plans cover it with a specialty-tier copay. Prior authorization typically requires:
- Documented T2D diagnosis (E11.xx ICD-10 code).
- Baseline A1C — usually 7.0% or higher.
- Trial and failure of metformin, unless contraindicated.
- Occasionally a prior trial of another GLP-1 or SGLT2 class.
If your initial PA is denied, the most common fix is adding documentation of metformin trial duration and A1C trend. Use our prior-auth guide and checklist to work through the appeal.
The downstream math most patients miss
Mounjaro’s list price looks large until you compare it to the cost of uncontrolled T2D. The American Diabetes Association estimates annual per-patient medical cost for diagnosed T2D at ~$13,700 as of 2024, with roughly $9,600 attributable to diabetes-specific care. Patients who achieve sustained A1C reduction to under 7.0% dramatically reduce complication risk — retinopathy, neuropathy, nephropathy, and MACE (major adverse cardiac events). Mounjaro’s SURPASS program showed A1C reductions of 1.8%–2.1% at maintenance doses, which is the largest in class.
A $25/month Mounjaro copay with a savings card = $300/year in direct drug cost plus maybe $400–$800 in specialist visits. Even at cash pay, $1,080/month × 12 = $12,960/year is often offset by avoided insulin, reduced complications, and (for many patients) weight loss that further reduces insulin resistance. Run the downstream health savings calculator for your specific numbers.